Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.

Liu HJ, Krymskaya VP, Henske EP.

Chest. 2019 Aug 19. pii: S0012-3692(19)31461-8. doi: 10.1016/j.chest.2019.08.005. [Epub ahead of print]

PMID:
31437431
2.

Syndecan-2: Old Player in a New Field.

Obraztsova K, Evans J, Krymskaya VP.

Am J Respir Cell Mol Biol. 2019 Jun;60(6):611-612. doi: 10.1165/rcmb.2019-0033ED. No abstract available.

3.

Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.

Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, Wight TN, Eruslanov E, Swartz MA, Krymskaya VP.

Am J Respir Cell Mol Biol. 2018 Dec;59(6):723-732. doi: 10.1165/rcmb.2018-0123OC.

PMID:
30095976
4.

Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.

Himes BE, Obraztsova K, Lian L, Shumyatcher M, Rue R, Atochina-Vasserman EN, Hur SK, Bartolomei MS, Evans JF, Krymskaya VP.

PLoS One. 2018 May 14;13(5):e0197105. doi: 10.1371/journal.pone.0197105. eCollection 2018.

5.

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Stepanova V, Dergilev KV, Holman KR, Parfyonova YV, Tsokolaeva ZI, Teter M, Atochina-Vasserman EN, Volgina A, Zaitsev SV, Lewis SP, Zabozlaev FG, Obraztsova K, Krymskaya VP, Cines DB.

J Biol Chem. 2017 Dec 15;292(50):20528-20543. doi: 10.1074/jbc.M117.799593. Epub 2017 Sep 27.

6.

Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Krymskaya VP, McCormack FX.

Annu Rev Med. 2017 Jan 14;68:69-83. doi: 10.1146/annurev-med-050715-104245. Review.

7.

Idiopathic multicentric Castleman's disease: a systematic literature review.

Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC.

Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17. Review.

PMID:
27063975
8.

Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Abramova E, James ML, Rue R, Liu AY, Ersumo NT, Guo CJ, Gow AJ, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.

9.

Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Ng HY, Oliver BG, Burgess JK, Krymskaya VP, Black JL, Moir LM.

J Cell Mol Med. 2015 Nov;19(11):2633-46. doi: 10.1111/jcmm.12593. Epub 2015 Aug 18.

10.

Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis.

Clements D, Dongre A, Krymskaya VP, Johnson SR.

PLoS One. 2015 May 15;10(5):e0126025. doi: 10.1371/journal.pone.0126025. eCollection 2015.

11.

Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Guo CJ, Abramova E, Golden TN, Sims M, James ML, Beers MF, Gow AJ, Krymskaya VP.

Am J Respir Cell Mol Biol. 2015 Jul;53(1):96-104. doi: 10.1165/rcmb.2014-0224OC.

12.

Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.

Goncharova EA, James ML, Kudryashova TV, Goncharov DA, Krymskaya VP.

PLoS One. 2014 Oct 31;9(10):e111476. doi: 10.1371/journal.pone.0111476. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118637.

13.

Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).

Krymskaya VP.

Expert Opin Orphan Drugs. 2014 Oct 1;2(10):1063-1074. Epub 2014 Aug 27.

14.

Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK.

Goncharova EA, Goncharov DA, James ML, Atochina-Vasserman EN, Stepanova V, Hong SB, Li H, Gonzales L, Baba M, Linehan WM, Gow AJ, Margulies S, Guttentag S, Schmidt LS, Krymskaya VP.

Cell Rep. 2014 Apr 24;7(2):412-423. doi: 10.1016/j.celrep.2014.03.025. Epub 2014 Apr 13.

15.

Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.

Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA.

Circulation. 2014 Feb 25;129(8):864-74. doi: 10.1161/CIRCULATIONAHA.113.004581. Epub 2013 Nov 22.

16.

Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.

Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP.

Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.

17.

Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder.

Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, Baybis M, Helfferich J, Okochi K, Strauss KA, Crino PB.

Sci Transl Med. 2013 Apr 24;5(182):182ra53. doi: 10.1126/scitranslmed.3005271.

18.

Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.

Goncharova EA, Khavin IS, Goncharov DA, Krymskaya VP.

Respir Res. 2012 Nov 27;13:109. doi: 10.1186/1465-9921-13-109.

19.

Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).

Hammes SR, Krymskaya VP.

Horm Cancer. 2013 Apr;4(2):70-7. doi: 10.1007/s12672-012-0128-4. Epub 2012 Nov 27. Review.

20.

Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion.

Medvetz DA, Khabibullin D, Hariharan V, Ongusaha PP, Goncharova EA, Schlechter T, Darling TN, Hofmann I, Krymskaya VP, Liao JK, Huang H, Henske EP.

PLoS One. 2012;7(11):e47842. doi: 10.1371/journal.pone.0047842. Epub 2012 Nov 6.

21.

Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP.

Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.

22.

TSC2 modulates cell adhesion and migration via integrin-α1β1.

Moir LM, Black JL, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2012 Oct 15;303(8):L703-10. doi: 10.1152/ajplung.00414.2011. Epub 2012 Aug 24.

23.

DHEA-S inhibits human neutrophil and human airway smooth muscle migration.

Koziol-White CJ, Goncharova EA, Cao G, Johnson M, Krymskaya VP, Panettieri RA Jr.

Biochim Biophys Acta. 2012 Oct;1822(10):1638-42. doi: 10.1016/j.bbadis.2012.06.012. Epub 2012 Jul 3.

24.

Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Krymskaya VP.

Am J Respir Cell Mol Biol. 2012 May;46(5):563-5. doi: 10.1165/rcmb.2011-0381ED. No abstract available.

25.

An RGS4-mediated phenotypic switch of bronchial smooth muscle cells promotes fixed airway obstruction in asthma.

Damera G, Druey KM, Cooper PR, Krymskaya VP, Soberman RJ, Amrani Y, Hoshi T, Brightling CE, Panettieri RA Jr.

PLoS One. 2012;7(1):e28504. doi: 10.1371/journal.pone.0028504. Epub 2012 Jan 12.

26.

β2-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein.

Goncharova EA, Goncharov DA, Zhao H, Penn RB, Krymskaya VP, Panettieri RA Jr.

Am J Respir Cell Mol Biol. 2012 Jan;46(1):48-54. doi: 10.1165/rcmb.2011-0217OC.

27.

mTORC2 is required for proliferation and survival of TSC2-null cells.

Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP.

Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11.

28.

Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells.

Moir LM, Ng HY, Poniris MH, Santa T, Burgess JK, Oliver BG, Krymskaya VP, Black JL.

Br J Pharmacol. 2011 Sep;164(1):83-92. doi: 10.1111/j.1476-5381.2011.01344.x.

29.

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA.

FASEB J. 2011 Jun;25(6):1922-33. doi: 10.1096/fj.10-175018. Epub 2011 Mar 2.

30.

Interferons modulate mitogen-induced protein synthesis in airway smooth muscle.

Goncharova EA, Lim PN, Chisolm A, Fogle HW 3rd, Taylor JH, Goncharov DA, Eszterhas A, Panettieri RA Jr, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2010 Jul;299(1):L25-35. doi: 10.1152/ajplung.00228.2009. Epub 2010 Apr 9.

31.

Vitamin D inhibits growth of human airway smooth muscle cells through growth factor-induced phosphorylation of retinoblastoma protein and checkpoint kinase 1.

Damera G, Fogle HW, Lim P, Goncharova EA, Zhao H, Banerjee A, Tliba O, Krymskaya VP, Panettieri RA Jr.

Br J Pharmacol. 2009 Nov;158(6):1429-41. doi: 10.1111/j.1476-5381.2009.00428.x. Epub 2009 Oct 8.

32.

Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.

Goncharova EA, Goncharov DA, Damera G, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2009 Oct;76(4):766-77. doi: 10.1124/mol.109.057042. Epub 2009 Jul 13.

33.

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Krymskaya VP, Goncharova EA.

Cell Cycle. 2009 Feb 1;8(3):403-13. Epub 2009 Feb 6. Review.

34.

Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Krymskaya VP.

Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26. Review.

35.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

PMID:
18094073
36.

The PP2A-associated protein alpha4 plays a critical role in the regulation of cell spreading and migration.

Kong M, Bui TV, Ditsworth D, Gruber JJ, Goncharov D, Krymskaya VP, Lindsten T, Thompson CB.

J Biol Chem. 2007 Oct 5;282(40):29712-20. Epub 2007 Aug 10.

37.

Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.

Goncharova EA, Krymskaya VP.

J Cell Biochem. 2008 Feb 1;103(2):369-82. Review.

PMID:
17541983
38.

Phosphodiesterases regulate airway smooth muscle function in health and disease.

Krymskaya VP, Panettieri RA Jr.

Curr Top Dev Biol. 2007;79:61-74. Review.

PMID:
17498547
39.
40.

Assays for in vitro monitoring of proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells.

Goncharova EA, Lim P, Goncharov DA, Eszterhas A, Panettieri RA Jr, Krymskaya VP.

Nat Protoc. 2006;1(6):2905-8.

PMID:
17406550
41.
42.

Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Goncharova EA, Goncharov DA, Spaits M, Noonan DJ, Talovskaya E, Eszterhas A, Krymskaya VP.

Am J Respir Cell Mol Biol. 2006 May;34(5):561-72. Epub 2006 Jan 19.

43.

Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP.

Am J Respir Cell Mol Biol. 2006 Apr;34(4):473-80. Epub 2005 Dec 30.

44.

Cross-talk between tuberin, calmodulin, and estrogen signaling pathways.

York B, Lou D, Panettieri RA Jr, Krymskaya VP, Vanaman TC, Noonan DJ.

FASEB J. 2005 Jul;19(9):1202-4. Epub 2005 Apr 25.

PMID:
15851513
45.

Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact.

Thangam EB, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP, Amrani Y, Panettieri RA Jr, Ali H.

FASEB J. 2005 May;19(7):798-800. Epub 2005 Mar 9.

PMID:
15758041
46.

Src is necessary and sufficient for human airway smooth muscle cell proliferation and migration.

Krymskaya VP, Goncharova EA, Ammit AJ, Lim PN, Goncharov DA, Eszterhas A, Panettieri RA Jr.

FASEB J. 2005 Mar;19(3):428-30. Epub 2004 Dec 20.

PMID:
15746183
47.

TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.

Goncharova E, Goncharov D, Noonan D, Krymskaya VP.

J Cell Biol. 2004 Dec 20;167(6):1171-82.

48.

Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent.

Kazi AS, Lotfi S, Goncharova EA, Tliba O, Amrani Y, Krymskaya VP, Lazaar AL.

Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L539-45. Epub 2003 Nov 21.

49.

Tumour suppressors hamartin and tuberin: intracellular signalling.

Krymskaya VP.

Cell Signal. 2003 Aug;15(8):729-39. Review.

PMID:
12781866
50.

Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation.

Krymskaya VP, Shipley JM.

Am J Respir Cell Mol Biol. 2003 May;28(5):546-50. No abstract available.

PMID:
12707009

Supplemental Content

Loading ...
Support Center